We’re just over a month away from our latest biotech bash in Boston, and with the agenda taking shape, we’re offering you a look at the proceedings today.
Our third annual iteration of “What’s Hot in Boston Biotech” features a mix of spotlight solo talks, candid stories, interactive discussions and more on a host of different hot topics in life sciences these days—from CRISPR-Cas9 gene editing to cancer immunotherapy to drug pricing. The event will take place on April 6 at Biogen’s campus on Binney St. in Cambridge, and you’ll hear from some the area’s top life sciences executives, scientists, and investors—folks like Chris Viehbacher, Phil Sharp, Deborah Dunsire, Greg Verdine and more.
The agenda is almost set—here’s a sneak peek. Tickets are going fast, but you still have some time to grab a discount if you register here before March 17. We’ll have more updates as they come. See you on April 6 at Biogen.
Author: Ben Fidler
Ben is former Xconomy Deputy Editor, Biotechnology. He is a seasoned business journalist that comes to Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming. Most recently, Ben was The Deal’s senior healthcare writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Ben wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act. Before switching to the healthcare beat, Ben was The Deal's senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others. Ben has a bachelor’s degree in English from Binghamton University.
View all posts by Ben Fidler
